The stocks below are all selling for less than $10 per share and have seen recent insider buying. Some of these companies have moved up recently, so I would wait for pullbacks and buy in stages only. I have provided links for each stock that verifies the insider buying filed with the SEC below.
Here are the stocks:
Doral Financial Group, Inc. (DRL) is trading around $1.30. Doral is a bank and is based in Puerto Rico. These shares have traded in a range between $1.03 to $6.81 in the last 52 weeks. The 50-day moving average is $1.19 and the 200-day moving average is $1.51. Earnings estimates are for a loss of 51 cents for 2011 and a profit of 7 cents for 2012. The book value is stated at $4.01. You can see the insider buying here.
There has been buying by a director and an officer at this company. The total of these two recent transactions is for about $24,000, which is not very significant; what is significant is that this is the first insider buying I can see filed for this company since 2008. I would watch this stock for more insider buying. If there is more buying, it could be a signal that insiders at this bank see real signs of a turnaround.
GTX, Inc. (GTXI) shares are trading at $4.11. GTXI is a biopharmaceutical company based in Tennessee. These shares have traded in a range between $1.90 to $4.30 in the last 52 weeks. The 50-day moving average is $2.75 and the 200-day moving average is $2.98. Earnings estimates for GTXI are for a loss of 73 cents per share in 2011 and a loss of 73 cents for 2012. Book value is stated at $1 per share. You can see the insider buying here.
One director recently purchased about 15,000 shares at $3.83 per share. This transaction is valued at about $57,000. Insiders might be seeing promising drug candidates in the pipeline. According to Yahoo Finance, this company has about $58 million in cash and almost no long term debt. These shares are trading well above their 50- and 200-day moving averages, so I would wait for pullbacks before considering a new purchase here.
MGIC Investment Corporation, Inc. (MTG) is trading around $8.07. MGIC provides private mortgage insurance and is based in Wisconsin. These shares have traded in a range between $6.48 to $11.98 in the last 52 weeks. The 50-day moving average is $8.80 and the 200-day moving average is $8.96. Earnings estimates for MTG is for a loss of 4 cents per share in 2011 and a profit of $1.27 for 2012. The book value is stated at $8 per share. You can see the repeated insider buying here.
This stock recently dropped from about $9.50, so insiders might be doing some bargain hunting. The drop in the stock price came when MGIC reported earnings that disappointed many investors. The company recently reported a loss of 17 cents per share, which missed analyst projections. You can read about its latest report here.
RXI Pharmaceuticals Corporation (RXII) shares are trading at close to $1. RXII is a biotechnology company and is based in Massachusetts. These shares have traded in a range between 88 cents to $4.67 in the last 52 weeks. The 50-day moving average is $1.36 and the 200-day moving average is $2.31. Earnings estimates are expected be negative for 2011. You can see the repeated insider buying here.
The CEO recently bought about 10,000 shares at 95 cents. Since this transaction only has a value of about $10,000, I would not read much into this purchase, especially since insiders were selling shares repeatedly over the past couple of years at much higher prices.
Asset Acceptance Capital Corp. (AACC) is trading around $5.48. Asset Acceptance purchases and collects receivable accounts and is based in Michigan. These shares have traded in a 52-week range between $3.55 to $8.16. The 50-day moving average is $5.54 and the 200-day moving average is $5.27. Earnings estimates for AACC are at 30 cents per share for 2011 and 47 cents for 2012. You can see the insider buying here.
A fund called the "D3 Family Canadian Fund LP" has been making significant purchases recently, which total about $1 million. The book value is reported to be $4.05. The estimates for earnings show significant growth next year, so between that and the current book value, this stock seems to be undervalued.